Influenza A Clinical Trial
Official title:
Randomised, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity Against Influenza Infection, Safety, Tolerability, and Pharmacokinetics of CC-42344 Via a Human Viral Challenge Model in Healthy Participants
Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood) will also be measured.
This is a single-center, phase 2a, randomized, double-blind, placebo-controlled study in healthy adult participants. The primary goal of this study is to assess the antiviral activity of orally administered CC-42344 in an influenza human viral challenge model, and to explore the impact of different dose levels on efficacy. In addition, the safety, tolerability, and pharmacokinetics will be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999554 -
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
|
Phase 1 | |
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Completed |
NCT02487173 -
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
| Completed |
NCT01701752 -
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT03207152 -
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
|
Phase 1 | |
| Terminated |
NCT05567783 -
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
|
Phase 2 | |
| Not yet recruiting |
NCT00987012 -
The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
|
N/A | |
| Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
| Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
| Completed |
NCT02623322 -
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
|
Phase 2 | |
| Completed |
NCT03196661 -
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
|
Phase 1 | |
| Recruiting |
NCT06191393 -
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
|
N/A | |
| Completed |
NCT06127108 -
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
|
N/A | |
| Completed |
NCT05163730 -
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
|
N/A | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Not yet recruiting |
NCT05787444 -
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
|
||
| Completed |
NCT05354115 -
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
|
N/A | |
| Completed |
NCT02014870 -
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05897515 -
LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia
|
N/A |